Indication
Neuroendocrine Skin Carcinoma
2 clinical trials
2 products
1 drug
Clinical trial
A Randomised, Placebo-controlled, Phase II Trial of Adjuvant Avelumab in Patients With Stage I-III Merkel Cell CarcinomaStatus: Recruiting, Estimated PCD: 2027-04-01
Product
AvelumabDrug
VarlilumabClinical trial
A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.Status: Withdrawn, Estimated PCD: 2021-07-15
Product
177Lu-DOTATOC